- Home
- SPCB vs FGEN Comparison
SPCB vs FGEN Comparison
Compare SPCB & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCB
- FGEN
- Stock Information
- Founded
- SPCB 1988
- FGEN 1993
- Country
- SPCB Israel
- FGEN United States
- Employees
- SPCB N/A
- FGEN N/A
- Industry
- SPCB Semiconductors
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SPCB Technology
- FGEN Health Care
- Exchange
- SPCB Nasdaq
- FGEN Nasdaq
- Market Cap
- SPCB 42.8M
- FGEN 38.4M
- IPO Year
- SPCB N/A
- FGEN 2014
- Fundamental
- Price
- SPCB $10.50
- FGEN $12.03
- Analyst Decision
- SPCB Strong Buy
- FGEN Strong Buy
- Analyst Count
- SPCB 1
- FGEN 2
- Target Price
- SPCB $18.00
- FGEN $146.50
- AVG Volume (30 Days)
- SPCB 120.0K
- FGEN 52.5K
- Earning Date
- SPCB 11-13-2025
- FGEN 11-11-2025
- Dividend Yield
- SPCB N/A
- FGEN N/A
- EPS Growth
- SPCB N/A
- FGEN N/A
- EPS
- SPCB N/A
- FGEN N/A
- Revenue
- SPCB $27,426,000.00
- FGEN $7,346,000.00
- Revenue This Year
- SPCB N/A
- FGEN N/A
- Revenue Next Year
- SPCB $29.31
- FGEN N/A
- P/E Ratio
- SPCB $14.19
- FGEN N/A
- Revenue Growth
- SPCB 2.90
- FGEN N/A
- 52 Week Low
- SPCB $2.81
- FGEN $4.50
- 52 Week High
- SPCB $18.95
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- SPCB 59.55
- FGEN 61.59
- Support Level
- SPCB $9.40
- FGEN $11.12
- Resistance Level
- SPCB $10.72
- FGEN $12.53
- Average True Range (ATR)
- SPCB 0.51
- FGEN 0.85
- MACD
- SPCB 0.16
- FGEN -0.05
- Stochastic Oscillator
- SPCB 89.62
- FGEN 75.11
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.